Background: Type 2 Diabetes mellitus is characterized by high blood glucose, insulin resistance, and relative lack of insulin. Common symptoms include increased thirst, frequent urination, and unexplained weight loss. Metformin, a biguanide agent acts primarily as an insulin sensitizer. Its primary clinical site of action is in the liver, improving hepatic insulin sensitivity and as a result, decreasing hepatic gluconeogenesis. Sitagliptin is an oral, highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of patients with Type 2 Diabetes Mellitus. Materials and methods: This is a Prospective, Comparative, Randomized and Parallel group study. Study was conducted in Type 2DM patients attending the outpatient department of Medicine in tertiary care center. Group I received Metformin 500 mg BD for 3 months, Group II received Sitagliptin 50 mg BD for 3 months and Group III Metformin 500 mg BD and Sitagliptin 50mg BD for 3 months. Result: In Group I at baseline was 147.24±9.50 mg/dl in Group II, it was151.25±9.50, and in Group III, it was 149.35 mg/dl with an SD of 9.56 mg/dl. The mean fasting blood glucose level in Group I after 3 months was 97.94 mg/dl with an SD of 8.61 mg/dl; in Group II, it was 95.58 mg/dl with an SD of 8.31 mg/dl, and in Group III, it was 91.58 mg/dl. The mean PPG level was 198.34±18.69 mg/dl at baseline, followed by 156.79±13.35 mg/dl after the 3rd month. In Group II, the mean PPG level was 201.88±18.64 mg/dl at baseline, followed by 135.58±12.75 mg/dl after the 3rd month. In Group III, the mean PPBG level was 200.74±17.75 mg/dl at baseline, followed by 131.84±13.48 mg/dl after the 3rd month. Conclusion: The present results suggested that sitagliptin combined with metformin is a well-tolerated and effective treatment for improving early glycaemic excursions and β-cell function, with reduced hypoglycaemia and no weight gain. These results confirmed the efficacy and safety of sitagliptin combined with metformin in patients with n